[1] Aier I, Semwal R, Sharma A, et al. A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer[J]. Cancer Epidemiol, 2019, 58: 104-110.
[2] Pachmann K, Clement J H, Schneider C P, et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer[J]. Clin Chem Lab Med, 2005, 43(6): 617-627.
[3] 陈 颐,王小林. 循环肿瘤细胞研究进展及其在PC诊疗中的应用[J]. 复旦学报(医学版), 2018, 45(1):119-136.
[4] Ma Y C, Wang L, Yu F L. Recent advances and prospects in the isolation by size of epithelial tumor cells (ISET) methodology[J]. Technol Cancer Res Treat, 2013, 12(4): 295-309.
[5] 丁善航,修典荣. 胰腺癌循环肿瘤细胞的富集、鉴定方法及预后的评估价值[J]. 中国微创外科杂志, 2019, 19(7):617-621.
[6] Yeo T, Tan S J, Lim C L, et al. Microfluidic enrichment for the single cell analysis of circulating tumor cells[J]. Sci Rep, 2016, 6: 22076.
[7] Chen K, Amontree J, Varillas J, et al. Incorporation of lateral microfiltration with immunoaffinity for enhancing the capture efficiency of rare cells[J]. Sci Rep, 2020, 10(1): 14210.
[8] Su Y, Tian Q, Pan D, et al. Antibody functional microsphere Integrated filter chip with inertial microflow for size-immune-capturing and digital detection of circulating tumor cells[J]. ACS Appl Mater Interfaces, 2019, 11(33): 29569-29578.
[9] 李兆申,王洛伟. 胰腺癌早期诊断[J]. 武警医学, 2004, 15(1):7-10.
[10] 李兆申. 胰腺癌早期诊断研究的现状与展望[J]. 解放军医学, 2009, 34(1):7-9.
[11] 刘艳辉,唐甜甜,孙丽丽. 肿瘤外周血循环细胞对胰腺癌的诊断价值[J]. 解放军医学院学报, 2013, 34(10):1045-1047.
[12] 吴 斌,陈敏捷,陈 飞,等. 循环肿瘤细胞对胰腺癌诊断价值的Meta分析[J]. 中国普通外科杂志, 2017, 26(3):271-280.
[13] Martini V, Timme B S, Fichtner F S, et al. Circulating tumor cells in pancreatic cancer: current perspectives[J]. Cancers (Basel), 2019, 11(11):1659.
[14] Hugenschmidt H, Labori K J, Brunborg C, et al. Circulating tumor cells are an independent predictor of shorter survival in patients undergoing resection for pancreatic and periampullary adenocarcinoma[J]. Ann Surg, 2020, 271(3): 549-558.
[15] Hugenschmidt H, Labori K J, Borgen E, et al. Preoperative CTC-detection by cellsearch((r)) is associated with early distant metastasis and impaired survival in resected pancreatic cancer[J]. Cancers (Basel), 2021, 13(3):485.
[16] Yin L, Pu N, Thompson E, et al. Improved assessment of response status in patients with pancreatic cancer treated with neoadjuvant therapy using somatic mutations and liquid biopsy analysis[J]. Clin Cancer Res, 2021, 27(3): 740-748.
[17] Wang Y, Yu X, Hartmann D,et al. Circulating tumor cells in peripheral blood of pancreatic cancer patients and their prognostic role: a systematic review and meta-analysis[J]. HPB (Oxford), 2020, 22(5): 660-669.
[18] Mandair D, Khan M S, Lopes A, et al. Prognostic threshold for circulating tumour cells in patients with pancreatic and midgut neuroendocrine tumours[J]. J Clin Endocrinol Metab, 2020,106(3):872-882.
[19] Chapman C G, Ayoub F, Swei E,et al. Endoscopic ultrasound acquired portal venous circulating tumor cells predict progression free survival and overall survival in patients with pancreaticobiliary cancers[J]. Pancreatology, 2020, 20(8): 1747-1754.
[20] Amantini C, Morelli M B, Nabissi M, et al. Expression profiling of circulating tumor cells in pancreatic ductal adenocarcinoma patients: biomarkers predicting overall survival[J]. Front Oncol, 2019, 9: 874.
[21] Poruk K E, Blackford A L, Weiss M J, et al. Circulating tumor cells expressing markers of tumor initiating cells predict poor survival and cancer recurrence in patients with pancreatic ductal adenocarcinoma[J]. Clin Cancer Res, 2017, 23(11): 2681-2690.
[22] Labib M, Wang Z, Ahmed S U, et al. Tracking the expression of therapeutic protein targets in rare cells by antibody mediated nanoparticle labelling and magnetic sorting[J]. Nat Biomed Eng, 2021, 5(1): 41-52.
[23] Sheng W, Ogunwobi O O, Chen T, et al. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip[J]. Lab Chip, 2014, 14(1): 89-98.
[24] Rivera-Baez L, Lohse I, Lin E, et al. Expansion of circulating tumor cells from patients with locally advanced pancreatic cancer enable patient derived xenografts and functional studies for personalized medicine[J]. Cancers (Basel), 2020, 12(4):1011.
[25] Nagarkar R, Patil D, Limaye S, et al. Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy[J]. Oncotarget, 2020, 11(45): 4195-4200.
[26] Wang D, Ge C, Liang W, et al. In Vivo enrichment and elimination of circulating tumor cells by using a black phosphorus and antibody functionalized intravenous catheter[J]. Adv Sci (Weinh), 2020, 7(17): 2000940.
[27] Franses J W, Philipp J, Missios P, et al. Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target[J]. Nat Commun, 2020, 11(1): 3303.
[28] Fernandez-Lazaro D, Hernandez J L G, Garcia A C, et al. Clinical perspective and translational oncology of liquid biopsy[J]. Diagnostics (Basel), 2020, 10(7):443.
[29] Hasanain A, Blanco B A, Yu J, et al. The importance of circulating and disseminated tumor cells in pancreatic cancer[J]. Surg Open Sci, 2019, 1(2): 49-55.
[30] 庄云英,张海燕,曾清芳. CRISPR/Cas9技术及其在胰腺癌研究中的应用进展[J]. 武警医学, 2020, 31(7):631-636.